Search Results for "101"

ONS member Susan Bruce, MSN, RN, AOCNS®, clinical nurse specialist at Duke Raleigh Cancer Center in North Carolina and member of the North Carolina Triangle ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss febrile neutropenia and nursing considerations for its management and prevention. This episode is part of an ongoing series about oncologic emergencies; the previous episode is linked in the episode notes. The advertising messages in this episode are brought to you by G1 Therapeutics, Inc. 

Cardiac tamponade typically presents gradually over time, and it can happen multiple times throughout a patient’s cancer care journey. Oncology nurses must stay cognizant of the warning signs and management approaches. ONS member Roberta Kaplow, RN, PhD, CCRN, AOCNS®, clinical nurse specialist at Emory University Hospital in Atlanta, GA, and member of the Metro Atlanta ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss the latest nursing management and prevention strategies for cardiac tamponade. This episode is part of a series about oncologic emergencies; the previous ones are linked in the episode notes.

Hypercalcemia of malignancy (HCM) affects about 30% of all patients with cancer. Patients with breast cancer that has metastasized to bone and patients with squamous cell lung cancer together account for more than half of all HCM cases. ONS member Marcelle Kaplan, RN, MS, CNS, CBCN®–Emeritus, AOCN®–Emeritus, breast oncology clinical specialist, and Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, discuss hypercalcemia of malignancy and its current treatment strategies. This episode is part of a series about oncologic emergencies; the other episodes are linked in the episode notes. 

ONS member Diane Cope, PhD, ARNP-BC, AOCNP®, director of nursing and oncology nurse practitioner at Florida Cancer Specialists and Research Institute in Fort Myers, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss tumor lysis syndrome and its current prevention and management strategies. This episode is part of a series about oncologic emergencies; the previous episodes are also linked in the episode notes. The advertising messages in this episode are paid for by clonoSEQ.

Early detection of bleeding directly affects survival rates for patients with cancer, but oncology nurses can improve outcomes by providing education and treatment for oncologic emergencies like thrombosis. ONS member Carrie Moore, MSN, OCN®, NE-BC, nurse manager at the Medical University of South Carolina in Charleston, and member of the South Carolina Low Country ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss bleeding disorders and thrombosis and their current management and treatment strategies. This episode is part of a series about oncologic emergencies; the previous episodes are linked in the episode notes.

ONS member Theresa Latchford, RN, MS, AOCNS®, BMTCN®, clinical nurse specialist at Stanford Health Care in Palo Alto, CA, and member of the Silicon Valley ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cytokine release syndrome and its associated immunotherapies. This episode is part of a new series about oncologic emergencies. We’ll add a link to future episodes in the show notes after the second episode next month.

“A couple of things I think are really important when you look at this class of drug: It developed by a concerted effort in cancer drug development to look at new agents that would be effective based on the mechanism. And then once they found a drug in this class that was beneficial, they further modified it to try to get better efficacy and less toxicity,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the nitrosoureas drug class.

“I think that there are certain agents that are so foundational in some diseases that they will remain. Whether they remain first-line, maybe not; maybe they’ll go to second line as we see things evolve with new agents. Some of these drugs have been very effective in the diseases in which they are used to treat patients. There’s a long term place in therapy for these, and I think that will still be using these,” Rowena Schwartz, PharmD, BCOP, FHOPA, known to many as “Moe,” professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, oncology clinical specialist at ONS, during a discussion about what oncology nurses need to know about antimetabolites. This episode is part of a series about drug classes, which we’ll include a link to in the episode notes. 

“I can't stress enough how often I get questions about, ‘Is this the paclitaxel doing this? Is this the docetaxel doing this?’ And coming up with strategies to kind of help get our patients through with supportive care is important. It's a really big opportunity for pharmacists and our nurses to really provide it and help our patients get through and show the knowledge that we have and to help them,” Dane Fritzsche, PharmD, BCOP, oncology informatics pharmacist at the Fred Hutchinson Cancer Center and University of Washington Medicine in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the plant alkaloid drug class.

“When I meet with patients, I try and remind them, ‘Yes, you do have these side effects that can happen’ and make sure that they’re informed, but also try and reassure them that not everyone gets it as severe as maybe the movies and TV shows portray,” Dane Fritzsche, PharmD, BCOP, informatics pharmacist from the Fred Hutchinson Cancer Center at the University of Washington Medicine in Seattle, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses need to know about alkylating agents for patients with cancer. This episode is the first in a series about drug classes, which we’ll include a link to in the episode notes.